Van Den Berg Management I Increased Its Amerisourcebergen (ABC) Position; Last Week Cellectis SA (ADR) (CLLS) Analysts

September 5, 2017 - By Louis Casey

Van Den Berg Management I Inc increased Amerisourcebergen Corp (ABC) stake by 28.58% reported in 2016Q4 SEC filing. Van Den Berg Management I Inc acquired 29,969 shares as Amerisourcebergen Corp (ABC)’s stock declined 1.76%. The Van Den Berg Management I Inc holds 134,837 shares with $10.54 million value, up from 104,868 last quarter. Amerisourcebergen Corp now has $17.55 billion valuation. The stock declined 0.20% or $0.16 reaching $80.08 on the news. About shares traded. AmerisourceBergen Corp. (NYSE:ABC) has risen 18.80% since September 5, 2016 and is uptrending. It has outperformed by 2.10% the S&P500.

Among 5 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cellectis had 7 analyst reports since April 5, 2016 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, June 6. The stock has “Buy” rating by Oppenheimer on Wednesday, August 16. The rating was initiated by Ladenburg Thalmann with “Buy” on Tuesday, April 5. The rating was initiated by Wells Fargo with “Outperform” on Tuesday, February 28. The firm has “Buy” rating by Oppenheimer given on Friday, June 2. The firm has “Buy” rating given on Thursday, August 24 by Jefferies. See Cellectis SA (ADR) (NASDAQ:CLLS) latest ratings:

24/08/2017 Broker: Jefferies Rating: Buy New Target: $47.0 Maintain
16/08/2017 Broker: Oppenheimer Rating: Buy New Target: $40.0 Maintain
06/06/2017 Broker: Jefferies Rating: Buy New Target: $47.0000 Maintain
02/06/2017 Broker: Oppenheimer Rating: Buy Maintain

Among 17 analysts covering AmerisourceBergen (NYSE:ABC), 8 have Buy rating, 0 Sell and 9 Hold. Therefore 47% are positive. AmerisourceBergen had 43 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, February 5 by UBS. FBR Capital maintained AmerisourceBergen Corp. (NYSE:ABC) on Thursday, February 4 with “Mkt Perform” rating. UBS maintained AmerisourceBergen Corp. (NYSE:ABC) rating on Friday, August 4. UBS has “Neutral” rating and $87 target. The stock of AmerisourceBergen Corp. (NYSE:ABC) earned “Outperform” rating by Credit Suisse on Tuesday, November 17. The firm earned “Mkt Perform” rating on Friday, November 4 by Leerink Swann. The stock of AmerisourceBergen Corp. (NYSE:ABC) earned “Mkt Outperform” rating by Avondale on Tuesday, October 4. The stock of AmerisourceBergen Corp. (NYSE:ABC) has “Neutral” rating given on Tuesday, June 7 by Bank of America. The firm has “Neutral” rating given on Tuesday, January 3 by Mizuho. The firm has “Hold” rating by Jefferies given on Wednesday, June 21. TheStreet upgraded the stock to “Buy” rating in Monday, July 27 report.

Van Den Berg Management I Inc decreased Superior Inds Intl Inc (NYSE:SUP) stake by 51,000 shares to 21,010 valued at $554,000 in 2016Q4. It also reduced Berkshire Hathaway Inc Del (BRKB) stake by 7,352 shares and now owns 274,558 shares. International Business Machs (NYSE:IBM) was reduced too.

About 312,549 shares traded or 138.94% up from the average. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 17.09% since September 5, 2016 and is downtrending. It has underperformed by 33.79% the S&P500.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has market cap of $827.46 million. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.